Promoting research partnerships to improve veterans’ health

NAVREF is proud to recognize Cohen Veterans Bioscience as our Champion Sponsor

NAVREF News Center

  • 14 Feb 2018 11:00 PM | Anonymous member (Administrator)

    Although funds have not been appropriated for the Department of Defense Peer Reviewed Medical Research Program (PRMRP), the PRMRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY18 funding opportunities.

    FY18 PRMRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in April 2018. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the Government, and funding of research projects received in response to these Program Announcements is contingent on the availability of Federal funds appropriated for the PRMRP.

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate, manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    Congressionally Directed Topic Areas. All applications submitted to the PRMRP must address at least one of the FY18 PRMRP Congressionally directed topic areas. As of the release date of this pre-announcement, the FY18 PRMRP Topic Areas have not been finalized. This pre-announcement should not be construed as an obligation by the Government to include any of these Topic Areas or others in the FY18 PRMRP. The potential FY18 PRMRP Topic Areas are as follows:

    • Acute Lung Injury
    • Antimicrobial Resistance
    • Arthritis
    • Burn Pit Exposure
    • Cardiomyopathy
    • Cerebellar Ataxia
    • Chronic Migraine and Post-Traumatic Headache
    • Chronic Pain Management
    • Congenital Heart Disease
    • Constrictive Bronchiolitis
    • Diabetes
    • Dystonia
    • Eating Disorders
    • Emerging Infectious Diseases
    • Endometriosis
    • Epidermolysis Bullosa
    • Focal Segmental Glomerulosclerosis
    • Fragile X Syndrome
    • Guillain-Barré Syndrome
    • Hepatitis B and C
    • Hereditary Angioedema
    • Hydrocephalus
    • Immunomonitoring of Intestinal Transplants
    • Inflammatory Bowel Diseases
    • Interstitial Cystitis
    • Lung Injury
    • Malaria
    • Metals Toxicology
    • Mitochondrial Disease
    • Musculoskeletal Disorders
    • Myotonic Dystrophy
    • Non-Opioid Pain Management
    • Nutrition Optimization
    • Pancreatitis
    • Pathogen-Inactivated Blood Products
    • Post-Traumatic Osteoarthritis
    • Pressure Ulcers
    • Pulmonary Fibrosis
    • Respiratory Health
    • Rett Syndrome
    • Rheumatoid Arthritis
    • Scleroderma
    • Sleep Disorders
    • Spinal Muscular Atrophy
    • Sustained-Release Drug Delivery
    • Tinnitus
    • Tuberculosis
    • Vascular Malformations
    • Women’s Heart Disease

    The mission of the PRMRP is to encourage, identify, and select military health-related research of exceptional scientific merit. Relevance to the healthcare needs of military Service members, Veterans, and their family members is a key feature of each FY18 PRMRP award mechanism.

    Clinical Trial Award

    • Assistant Professor level or above (or equivalent)
    • Preproposal submission is required; application submission is by invitation only.
    • Supports the rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the topic area(s) of interest.
    • Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.
    • Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration by the PRMRP application submission deadline.
    • Funding limit not defined; requested funding must be appropriate for the scope of work proposed
    • Maximum period of performance is 4 years

    Discovery Award

    • Postdoctoral fellow or clinical fellow (or equivalent) and above
    • Supports the exploration of a highly innovative new concept or untested theory.
    • Not intended to support the logical progression of an already established line of questioning.
    • Clinical trials will not be funded.
    • Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborators, and their organization(s).
    • Maximum of $200,000 for direct costs (plus indirect costs)
    • Maximum period of performance is 18 months

    Focused Program Award

    • Full Professor level or above (or equivalent)
    • Preproposal submission is required; application submission is by invitation only.
    • Supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal.
    • Projects should work together to answer critical questions, resolve differing hypotheses, and translate laboratory findings to clinical applications.
    • Projects may range from exploratory/hypothesis-developing through small-scale clinical trials that together will address the overarching goal/question.
    • Research team of highly qualified, multidisciplinary project leaders should be led by a PI with demonstrated success in directing large, focused projects.
    • Maximum of $10 million for total costs (includes direct and indirect costs)
    • Maximum period of performance is 4 years

    Investigator-Initiated Research Award

    • Assistant Professor level or above (or equivalent)
    • Preproposal submission is required; application submission is by invitation only.
    • Supports research that will make an original and important contribution to the field of research or patient care in the topic area(s) of interest.
    • Partnering PI Option available.
    • Clinical trials will not be funded.
    • Maximum of $1.2 million for direct costs (plus indirect costs)
    • Maximum of $1.5 million for direct costs (plus indirect costs) for applications including a Partnering PI Option
    • Maximum period of performance is 3 years

    Technology/ Therapeutic Development Award

    • Assistant Professor level or above (or equivalent)
    • Supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, or quality of life.
    • Product-oriented (e.g., device, drug, clinical guidelines). The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.
    • Clinical trials will not be funded.
    • Preproposal submission is required; application submission is by invitation only.
    • Maximum of $3.0 million for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

    Applications must be submitted through the federal government's single-entry portal, Grants.gov. Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the PRMRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 13 Feb 2018 9:52 AM | Anonymous member (Administrator)

    Although funds have not been appropriated for the FY18 Department of Defense Ovarian Cancer Research Program (OCRP), the OCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY18 funding opportunities.

    FY18 OCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in March 2018.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the Government, and funding of research projects received in response to these Program Announcements is contingent on the availability of federal funds appropriated for the OCRP.

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    The mission of the OCRP is to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of Service members, Veterans, retirees, their family members, and all women impacted by this disease.

    Clinical Development Award

    • Must be an independent investigator at or above the level of Assistant Professor (or equivalent).
    • Supports the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life.
    • Near-term impact is expected.
    • Preclinical studies in animals are not allowed.
    • Small-scale clinical trials (Phase 0, Phase 1, Pilot), studies enriching a clinical trial, and projects related to or associated with ongoing or completed clinical trials are allowed.
    • Preliminary data are required.
    • Optional Nested Early-Career Investigator (ECI):  Applications proposing clinical trials and having an ECI that meets the criteria outlined in the Program Announcement/Funding Opportunity will qualify for a higher level of funding.
    • Submission of a Letter of Intent is required prior to full application submission.
    • Maximum funding of $600,000 for direct costs (plus indirect costs).
    • With ECI option the maximum funding is $800,000 for direct costs (plus indirect costs).
    • Maximum period of performance is 3 years.

    Omics Consortium Development Award

    • Must be an independent investigator at the Associate Professor level or above (or equivalent)
    • ·        Supports a multi-institutional research effort conducted by leading cancer researchers and advocates that focuses on the origin of ovarian cancer, with an emphasis on risk stratification, screening and early detection.
    • ·        Funds support assembling consortium members and laying the groundwork for the research project, including proof of concept.
    • ·        Ovarian cancer advocate(s) are required on the research team.
    • ·        Funded applicants will be eligible to compete for the consortium award, which will support the execution of the full research project and is anticipated to be offered in FY20, pending availability of funds.
    • Submission of a Letter of Intent is required prior to full application submission
    • Maximum funding of $400,000 for direct costs (plus indirect costs). 
    • Period of performance not to exceed 2 years.

    Investigator-Initiated Research Award

    • Must be an independent investigator at or above the level of Assistant Professor (or equivalent).
    • Supports meritorious basic and clinically oriented research in ovarian cancer.
    • Impact is an important review criterion.
    • Preliminary data are required.
    • Clinical trials are not allowed. 
    • Pre-application is required; application is by invitation only.
    • Maximum funding of $450,000 for direct costs (plus indirect costs).
    • Maximum period of performance is 3 years.

    Ovarian Cancer Academy Award – Early-Career Investigator

    • Must be within 3 years of his/her last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent as of the full application submission deadline.  A letter attesting to eligibility is required.
    • Supports the addition of new ECIs to the unique, interactive virtual academy that provides intensive mentoring, national networking, and a peer group for junior faculty.
    • ECIs whose ability to commit to conducting ovarian cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.
    • A Designated Mentor who is an experienced ovarian cancer researcher with ovarian cancer funding is required.
    • A Designated Mentor may only mentor one ECI candidate.
    • The Designated Mentor is not required to be at the same institution as the ECI.
    • Preliminary data are required.
    • Clinical trials are allowed.
    • Submission of a Letter of Intent is required prior to full application submission.
    • Maximum funding of $725,000 for direct costs (plus indirect costs).
    • Maximum period of performance is years.

    Pilot Award

    • Investigators at or above the postdoctoral level (or equivalent).
    • Supports innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will drive the field of ovarian cancer research forward.
    • Innovation and Impact are important review criteria.
    • Goal is to develop preliminary data; thus, preliminary data are not required, but are allowed.
    • Clinical trials are not allowed.
    • Pre-application is required and blinded; application submission is by invitation only.
    • Maximum funding of $250,000 for direct costs (plus indirect costs).
    • Maximum period of performance is 2 years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Applications must be submitted through the Federal Government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, go to the CDMRP website (http://cdmrp.army.mil) and select Subscribe to Funding Opportunities & Program Communications.  For more information about the OCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 9 Feb 2018 9:32 AM | Anonymous member (Administrator)

    Due to the current Continuing Resolution, the FY18 Defense Appropriations bill has not been passed. Although funds have not been appropriated for the Department of Defense Bone Marrow Failure Research Program (BMFRP), the BMFRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY18 funding opportunities.

    FY18 BMFRP Program Announcement and General Application Instructions for the following award mechanism is anticipated to be posted on Grants.gov in April 2018. Pre-application and application deadlines will be available when the Program Announcement is released. This pre-announcement should not be construed as an obligation by the Government, and funding of research projects received in response to this Program Announcement is contingent on the availability of Federal funds appropriated for the BMFRP.

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    Idea Development Award

    Established Investigators:
    Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree
    or
    Early-Career Investigators:
    Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or on family medical leave) at the time of application submission deadline are eligible.

    • Preproposal is required; full application submission is by invitation only.
    • Supports innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the vision to understand and cure bone marrow failure (BMF).
    • Strong BMF research team.
    • May include relevant preliminary data.
    • Maximum funding of $325,000 in direct costs (plus indirect costs)
    • Period of performance not to exceed 2 years
    • Clinical trials will not be supported.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcement and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov website. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov website. Submission deadlines are not available until the Program Announcement is released. For email notification when the Program Announcement is released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the BMFRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 5 Feb 2018 1:21 PM | Anonymous member (Administrator)

    Due to the current Continuing Resolution, the Fiscal Year 2018 (FY18) Defense Appropriations bill has not been passed. Although funds have not been appropriated for the Department of Defense Breast Cancer Research Program (BCRP), the BCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY18 funding opportunities.

    FY18 BCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in March 2018.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the Government, and funding of research projects received in response to these Program Announcements is contingent on the availability of Federal funds appropriated for the BCRP.

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    Applications submitted to the FY18 BCRP must address one or more of the following overarching challenges:

    • Prevent breast cancer (primary prevention)
    • Identify determinants of breast cancer initiation, risk, or susceptibility
    • Distinguish deadly from non-deadly breast cancers
    • Conquer the problems of over diagnosis and overtreatment
    • Identify what drives breast cancer growth; determine how to stop it
    • Identify why some breast cancers become metastatic
    • Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
    • Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
    • Eliminate the mortality associated with metastatic breast cancer

    Breakthrough Award

    ·       Investigators at all academic levels (or equivalent)

    • Senior postdoctoral fellows who do not meet the eligibility requirements of the Breakthrough Fellowship Award are encouraged to apply under Funding Levels 1 and 2
    • Supports promising research that has the potential to lead to or make breakthroughs in breast cancer.
    • Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.
    • Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application.
    • Four different funding levels, based on the scope of research, are available.  It is the responsibility of the PI to select the funding level that is most appropriate for the research proposed.  The funding level should be selected based on the scope of the research project, rather than the amount of the budget.

    The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level:

    • Funding Level 1:  Innovative, high-risk/high-reward research that is in the earliest stages of idea development.  Research with potential to yield new avenues of investigation.  Proof of concept.  No preliminary data required.
    • Funding Level 2:  Research that is already supported by preliminary data and has potential to make significant advancements toward clinical translation.
    • Funding Level 3:  Advanced translational studies that have potential for near-term clinical investigation.  Small-scale clinical trials may apply.
    • Funding Level 4:  Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer.  Near-term clinical impact is expected.  Human clinical testing is required. 
    • PIs are expected to have experience in successfully leading large-scale projects.

    Funding Levels 1 and 2:

    ·       Submission of a Letter of Intent is required prior to full application submission.

    ·       Each PI may submit only one application as a PI or Initiating PI.  There are no limitations on the number of applications for which an investigator may be named as a Partnering PI.  However, applicants are discouraged from submitting as a Partnering PI on multiple applications unless they are clearly unique, meaningful collaborations addressing distinct research questions.

    ·       Additional funds are available for applications submitted under the Partnering PI Option.

    ·       Clinical trials are not allowed.

    Funding Levels 3 and 4:

    ·       Preproposal is required; application submission is by invitation only.

    ·       Each PI may submit only one application as a PI or Initiating PI.  There are no limitations on the number of applications for which an investigator may be named as a Partnering PI.  However, applicants are discouraged from submitting as a Partnering PI on multiple applications unless they are clearly unique, meaningful collaborations addressing distinct research questions.

    ·       Additional funds are available for Funding Level 3 applications submitted under the Partnering PI Option.

    ·       PIs must include two or more breast cancer advocates on their research team.

    • Clinical trials are allowed.

    Funding Level 1:

    Maximum funding of $375,000 for direct costs (plus indirect costs)

    Maximum period of performance is 3 years

    Funding Level 1 – Partnering PI Option:

    Maximum funding of $600,000 for direct costs (plus indirect costs)

    Maximum period of performance is 3 years

    Funding Level 2:

    Maximum funding of $750,000 for direct costs (plus indirect costs)

    Maximum period of performance is 3 years

    Funding Level 2 – Partnering PI Option:

    Maximum funding of $1M for direct costs (plus indirect costs)

    Maximum period of performance is 3 years

    Funding Level 3:

    Maximum funding of $2.5M in direct costs (plus indirect costs)

    Maximum period of performance is 4 years

    Funding Level 3 – Partnering PI Option:

    Maximum funding of $4M for direct costs (plus indirect costs)

    Maximum period of performance is 4 years

    Funding Level 4 and Funding Level 4 – Partnering PI Option:

    Maximum funding of $10M for direct costs (plus indirect costs)

    Maximum period of performance is 4 years

    Breakthrough Fellowship Award

    As of the application submission deadline, all eligible PIs must have:

    ·        Successfully completed the requirements for a doctoral or medical degree, and

    ·        Been in the laboratory or clinical research setting in which the proposed research is to be performed for no more than 2 years, and

    ·        A total of less than 4 years’ experience in a postdoctoral fellowship or mentored clinical research training program (excludes any clinical residency or fellowship training)

    Mentor

    Must have breast cancer research experience, including current funding and recent publications

    ·       Supports exceptionally talented, “best and brightest” recent doctoral or medical graduates in pursuit of promising research that has the potential to lead to or make breakthroughs in breast cancer.

    ·       Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.

    ·       Individualized researcher development plan and mentorship should prepare the PI for an independent career at the forefront of breast cancer research or patient care.

    ·       The PI is not required to have previous experience in breast cancer research.

    ·       Maximum funding of $300,000 for direct costs (plus indirect costs)

    • Maximum period of performance is 3 years

    Era of Hope Scholar Award

    Independent, non-mentored investigators within 6 years of their last training position (e.g., postdoctoral fellowship, medical residency, clinical fellowship) as of the application submission deadline

    ·       Submission of a Letter of Intent is required prior to full application submission.

    ·       Supports exceptionally talented, creative early-career scientists who have demonstrated that they are the “best and brightest” in their fields.

    ·       PIs should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention.

    ·       PIs must exhibit strong potential for leadership in breast cancer.

    • PIs are required to include breast cancer advocates on their research team.

    ·       Maximum funding of $2.5M for direct costs (plus indirect costs)

    • Maximum period of performance is 4 years

    Innovator Award

    Associate Professor or above (or equivalent).

    ·       Supports visionary individuals who have demonstrated creativity, innovative work, and leadership in any field.

    ·       Provides opportunity to pursue novel, visionary, high-risk ideas that will accelerate progress toward ending breast cancer.

    ·       PIs must include breast cancer advocates on their research team.

    • Preproposal is required; application submission is by invitation only.

    ·       Maximum funding of $5M for direct costs (plus indirect costs).

    • Maximum period of performance is 4 years

    Distinguished Investigator Award

    Assistant Professor or above (or equivalent) and more than 6 years beyond the PI’s last training position as of the application submission deadline

    ·       Seeks new paradigms in breast cancer research by supporting investigators who are established and recognized leaders with a renowned reputation in their field and who propose a fundamental shift from their track record of research.

    ·       Does not support continuation of or minor advancement from the PI’s published line of research.

    ·       If the PI is not an established breast cancer researcher, he/she must clearly articulate a motivation and commitment for proposing a conceptual shift in his/her research and must include at least one collaborator with breast cancer expertise.

    ·       PIs must include two or more breast cancer advocates on their research team.

    ·       High-risk/high-reward projects pursuing innovative new paradigms are encouraged, but not required.

    • Preproposal is required; application submission is by invitation only.

    ·       Maximum funding of $3M for direct costs (plus indirect costs)

    • Maximum period of performance is 4 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the BCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 5 Feb 2018 10:39 AM | Anonymous member (Administrator)

    Due to the current Continuing Resolution, the Fiscal Year 2018 (FY18) Defense Appropriations bill has not been passed. Although funds have not been appropriated for the Department of Defense Multiple Sclerosis Research Program (MSRP), the MSRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY18 funding opportunities.

    FY18 MSRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in April 2018. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the Government, and funding of research projects received in response to these Program Announcements is contingent on the availability of Federal funds appropriated for the MSRP.

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    Applications submitted to the FY18 MSRP must address at least one of the following Focus Areas:

    1) Obstacles to Remyelination and/or Obstacles to Axonal Protection in MS

    • Examples of acceptable studies include, but are not limited to, the roles of inhibitory factors, trophic factors, cell-cell interactions, and cell intrinsic factors.
    • Utilization and/or development of models that reflect the disease progression and translational approaches to evaluate benefit are encouraged.

    Note: Projects addressing the basic mechanisms of demyelination and neurodegeneration, inflammation or prevention of secondary injury following inflammation will not be considered for funding.

    (2) Correlates of Disease Activity and Progression in MS

    Studies may identify or validate correlates of disease activity and progression using pre-existing specimens and/or data acquired from well-characterized, adequately controlled, and sufficiently powered patient cohorts.

    • Correlates include clinical outcome measures, patient self-reported measures, and imaging and non-imaging biomarkers.
    • Examples of acceptable cohorts for study include controlled clinical trials, observational studies, and registries. Analyses may utilize existing clinical data and outcome measures, specimens, and/or imaging data.

    Note: The study must leverage pre-existing specimens and/or data that are available at the time of application submission; collection of additional data on the existing cohort is allowed.

    (3) Biology and Measurements of MS Symptoms (Exploration – Hypothesis Development Award ONLY!)

    • Symptoms may include pain, fatigue, cognitive dysfunction, visual impairment, motor impairment, impaired mobility, loss of bladder control, sexual dysfunction, depression, and anxiety.
    • Examples of acceptable studies include, but are not limited to, the following: development of measurements for future interventional studies to alleviate symptoms, rehabilitation, mechanisms underlying symptoms of MS, development and/or validation of outcome measures and tools for symptoms, and observational studies on the prevalence or significance of symptoms.

    Note: Studies of disease-modifying or regenerative therapies that secondarily impact symptoms will not be considered for funding.

    Exploration - Hypothesis Development Award

    Independent investigators at or above the level of Assistant Professor (or equivalent)

    All applications submitted in this funding opportunity must address at least one of the following Focus Areas:
    (1) Obstacles to Remyelination and/or Obstacles to Axonal Protection in MS
    (2) Correlates of Disease Activity and Progression in MS
    (3) Biology and Measurements of MS Symptoms

    • Pre-application submission is required; application submission is by invitation only.
    • Supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the MS research field.
    • Preliminary data not required.
    • Maximum funding of $150,000 for direct costs (plus indirect costs)
    • Maximum period of performance is 2 years
    • Clinical trials not allowed.

    Investigator-Initiated Research Award

    Independent investigators at or above the level of Assistant Professor (or equivalent)

    All applications submitted in this funding opportunity must address at least one of the following Focus Areas:
    (1) Obstacles to Remyelination and/or Obstacles to Axonal Protection in MS
    (2) Correlates of Disease Activity and Progression in MS

    • Pre-application submission is required; application submission is by invitation only.
    • Supports highly rigorous, high-impact research with the potential to make an important contribution to MS research and/or patient care.
    • Preliminary data required.
    • Maximum funding of $600,000 for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years
    • Clinical trials not allowed.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov. Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the MSRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 4 Jan 2018 4:48 PM | Anonymous member (Administrator)

    Funding Available for FUS + Cancer Immunotherapy Projects 


    In June, the Foundation partnered with the Cancer Research Institute to advance the development of new focused ultrasound (FUS) and cancer immunotherapy treatments. Both organizations recognize the intersection of the latest developments in FUS therapy and cancer immunotherapy offers a highly promising opportunity for combination approaches to treat a variety of cancers.

    As a key component of this partnership, we established a grant program to jointly fund research projects that will help investigate new focused ultrasound and cancer immunotherapy combination treatments.

    This first request for proposals seeks preclinical projects to answer the following research question:

    How do different “modes” of focused ultrasound (i.e. ablative vs. non-ablative, thermal vs. mechanical) compare in terms of the immune response generated, and how does this immune response correlate with biological, acoustic and imaging metrics?

    We encourage you to apply and share this opportunity with your colleagues. 

    Projects are eligible for up to $200,000 over two years, and letters of intent are due January 15. 


  • 20 Dec 2017 11:11 AM | Anonymous member (Administrator)

    New for the 2018 ASCO Annual Meeting, there will be a Merit Award for a VA fellow/oncology trainee.  The Conquer Cancer Foundation Merit Awards are awarded to fellows/oncology trainees whose research is addressed in high-quality abstracts submitted to the ASCO Annual Meeting and recognized for its scientific merit. 

     

    For the purposes of this award, a VA fellow or oncology trainee is someone:

    (1) who has performed work at a Veterans Affairs facility or,

    (2) whose research describes Veterans Affairs patients, or

    (3) who uses data from Veterans Affairs in his or her research.

    Your abstract must demonstrate one of the above qualifying criteria AND be selected as high-quality for scientific merit. 

     

    The deadline for abstract submissions for the ASCO Annual Meeting is February 13, 2018.  https://asco.confex.com/asco/2018/cfp.cgi


  • 28 Nov 2017 1:43 PM | Anonymous member (Administrator)

    If you are conducting NIH-funded research that involves human subjects, or are considering applying to NIH for support of such research, we want to call your attention to important changes that may affect how you:

    • select the right NIH funding opportunity announcement
    • write the research strategy and human subjects sections of your application
    • comply with appropriate policies and regulations

    First, familiarize yourself with the new PHS Human Subject and Clinical Trial Information form. For application due dates of January 25, 2018, and beyond, you will be required to use an updated application forms package (FORMS-E), which includes the new human subject and clinical trial form. This form requests human subject and clinical trials information at the study level using discrete form fields, which is a change from current practice. Contract proposals will also require this information. Learn about the new form here.

    Second, take a moment to answer these four questions about your current or proposed research:

    1) Does the study involve human participants?

    2) Are the participants prospectively assigned to an intervention?

    3) Is the study designed to evaluate the effect of the intervention on the participants?

    4) Is the effect that will be evaluated a health-related biomedical or behavioral outcome?

    If the answer to all four questions is yes, then your proposed research meets the NIH definition of a clinical trial. Clarified and broadened in 2014, the definition encompasses a wide range of trial types: mechanistic, exploratory/developmental, pilot/feasibility, behavioral, and more. NIH expanded the clinical trial definition in response to widespread calls from diverse stakeholders for improved reporting of research milestones and outcomes, and for assuring maximal transparency.

    Need help determining whether your study would be considered by NIH to be a clinical trial? See our webpage on the definition that includes case studies, FAQs and other resources that can help. Still unsure?  Contact your NIH program official or the scientific point of contact listed on the funding opportunity announcement to which you are applying.

    Third, familiarize yourself with NIH policy changes related to enhancing stewardship of clinical trials.

    NIH made a number of policy changes to improve the stewardship of clinical trials across the life cycle of the trial. We encourage you to familiarize yourself with all that is changing, including:

    • the requirement to apply to an FOA that specifically allows for the submission of clinical trial applications for due dates beginning January 25, 2018.
    • Good Clinical Practice training expectations for NIH staff, grantees, and contractors that went into effect January 2017.
    • updated peer review criteria that will be included in FOAs for clinical trial applications and solicitations for due dates on/after January 25, 2018.
    • new Human Subject Information form requirements for clinical trials that will be included in updated application forms (FORMS-E) for due dates on/after January 25, 2018, and contract solicitations published as of January 25, 2018.
    • use of a single IRB for non-exempt, multi-site clinical trials for application due dates on/after January 25, 2018.
    • expanded ClinicalTrials.gov registration and reporting to include all NIH supported clinical trials.

    Improving the design, efficiency, and transparency of clinical trials is important because it:

    • respects our ethical obligation to participants to maximize the use of the knowledge from the trials in which they participate
    • facilitates design of clinical trials while reducing unnecessary duplication
    • promotes broad, timely, and responsible dissemination of research information and results
    • fosters responsible stewardship of the public’s investment in biomedical research

    We have developed a new Clinical Trial Requirements for NIH Grantees and Contractors web page to bring together all the information you need to know.  Please review this information carefully.  Your attention to detail will be critical to ensuring successful funding of your clinical trial awards.

    We will be putting out a series of reminder policy notices, training opportunities, and other resources in the NIH Guide to Grants and Contracts, in the NIH Extramural Nexus, and on my blog

    The success of clinical trials relies on the public trust in scientific rigor and ethical oversight.  We all play a critical role in this process.  We are most grateful to you for your help and support.


  • 27 Nov 2017 9:29 AM | Anonymous member (Administrator)

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation.  The managing agent for the Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    http://cdmrp.army.mil/funding/dmrdp

    AIMM Research Award

    • Independent investigators at all academic levels (or equivalent)
    • Supports highly creative and conceptually innovative high-risk research with the potential to accelerate critical discoveries or major advancements that will significantly impact military health and medicine.
    • Supports novel research concepts and development of enabling technologies.
    • Supports applied research efforts that initiate or enhance potential game-changers; clinical trials are not allowed.
    • Impact and Innovation are important aspects of the AIMM initiative.
    • Projects proposed should be relevant to at least one DoD medical research program area.  However, broadly applicable research projects with the potential to benefit multiple DoD medical research program areas are encouraged. 
    • Applications using synthetic or systems biology-based approaches are highly encouraged.
    • Pre-application (Letter of Intent) is required.
    • Maximum funding of $350,000 for direct costs (plus indirect costs).
    • Maximum period of performance is 18 months.

    A pre-application (Letter of Intent) is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcement and General Application Instructions available for electronic downloading from the Grants.gov website at https://www.grants.gov/.  The application package containing the required forms for each award mechanism are found on Grants.gov.  A listing of all USAMRMC funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Applications must be submitted through the federal government’s single-entry portal, Grants.govFor email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-682-5507

    help@eBrap.org


  • 16 Nov 2017 11:47 AM | Anonymous member (Administrator)

    VA’s Office of Research and Development (ORD) has partnered with the National Cancer Institute (NCI) to increase the opportunities for Veterans to participate in NCI funded clinical trials.  This effort, known as the NCI And VA Interagency Group to Accelerate Trials Enrollment (NAVIGATE), seeks to fund infrastructure at selected VA Medical Centers to help with overcoming recruitment barriers and facilitating participation in NCI National Clinical Trials Network (NCTN) and NCI Community Oncology Research Program (NCORP) studies.

    The Request for Applications (RFA) can be read here . Interested sites should note the following:

    • Only one application per VA medical center is permitted.
    • There is a Letter of Intent deadline of November 29, 2017 to indicate interest in submitting an application. 
    • Full applications are due on January 10, 2018. 
    • VA Medical Centers interested in submitting an application must work with in collaboration with their VA non-profit corporations/research and education foundations.

    Questions can be directed to CSP@va.gov


1717 K ST NW Suite 900

Washington, DC 20006

P: 301-656-5005  |  admin@navref.org

Powered by Wild Apricot Membership Software